TAIZHOU, China, Sept. 11,
2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc.
(NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty
pharmaceutical company focusing on the research, development,
manufacturing, marketing, and sales of Traditional Chinese Medicine
Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and
After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM
Homologous Supplements ("TCMHS") announced today that it has
been granted to establish the Taizhou Research Center for
Advanced TCMP Engineering Techniques (the "Center") by
the Taizhou Science and Technology Bureau, a department of the
Taizhou city government.
The Center, a project founded by the Taizhou Tech
Innovation Assembly Program, is supported by the Taizhou
government. With the establishment of the Center, the Company is
expected to further its lead on research and development of
Advanced TCMPs and receive additional benefits when marketing its
Advanced TCMP products in the future.
Mr. Feng Zhou, Chief Executive
Officer and Director of China SXT, commented, "Being granted to
participate in the Taizhou Tech Innovation Assembly Program is a
true testimony to our continuous effort in the research and
development of TCMPs. The Center allows us to further strengthen
our research and development capabilities and advance our TCMP
engineering technologies, which leads us one step closer to
achieving our goal of becoming a leading specialty pharmaceutical
company in TCMPs."
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu
Province, China, China SXT Pharmaceuticals, Inc. is an
innovative pharmaceutical company focusing on the research,
development, manufacture, marketing and sales of traditional
Chinese medicine pieces, which is a type of Traditional Chinese
Medicine that has been processed to be ready for use. For more
information, please visit www.sxtchina.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Specifically, the Company's statements regarding the
closing of the proposed private placement are forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; the growth of the pharmaceutical
market, particularly the Traditional Chinese Medicine Pieces
("TCMPs") market, in China; reputation and brand; the impact
of competition and pricing; government regulations; fluctuations in
general economic and business conditions in China and the
international markets the Company serves and assumptions underlying
or related to any of the foregoing and other risks contained in
reports filed by the Company with the Securities and Exchange
Commission. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the U.S. Securities and Exchange
Commission, which are available for review at www.sec.gov. The
Company undertakes no obligation to publicly revise these
forward - looking statements to reflect events or
circumstances that arise after the date hereof.
For more information, please contact:
At the Company:
Alex Shi, CFO
Email: alexyaoshi@qq.com
ICR, LLC
Rose Zu
Email: ir@sxtchina.com
Phone: +1-646-277-1287
View original
content:http://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-granted-to-establish-taizhou-research-center-for-advanced-tcmp-engineering-techniques-300915816.html
SOURCE China SXT Pharmaceuticals, Inc.